Impact of Lebrikizumab on Patient-Reported Outcomes in Atopic Dermatitis: Prospective and Post Hoc Analyses of a Phase 2b Clinical Trial Demonstrate Clinically Meaningful Improvements

Main Article Content

E Guttman-Yassky
A Blauvelt
L Eichenfield
A Paller
A Armstrong
J Drew
R Gopalan
E Simpson

Keywords

Atopic Dermatitis, Biologic, Lebrikizumab

Abstract

Abstract not available.

References

1. Silverberg et al., Br J Dermatol., 2019;181:554-565.

2. Guttman-Yassky et al., JAMA Derm., 2020;156:411-420.